T1	Age 15 25	4-year-old
T2	Sex 26 29	boy
T3	Disease_disorder 55 68	Blau syndrome
E1	Disease_disorder:T3 
T4	Disease_disorder 142 151	arthritis
E2	Disease_disorder:T4 
T5	Biological_structure 126 131	ankle
T6	Biological_structure 136 141	wrist
T7	Disease_disorder 152 165	tenosynovitis
E3	Disease_disorder:T7 
T8	Sign_symptom 186 190	rash
E4	Sign_symptom:T8 
T9	Biological_attribute 175 185	eczematous
T10	Detailed_description 167 174	diffuse
R1	MODIFY Arg1:T10 Arg2:E4	
R2	MODIFY Arg1:T9 Arg2:E4	
T11	Disease_disorder 196 203	uveitis
E5	Disease_disorder:T11 
T12	Disease_disorder 242 252	granulomas
E6	Disease_disorder:T12 
T13	Detailed_description 229 241	noncaseating
R3	MODIFY Arg1:T13 Arg2:E6	
T14	Diagnostic_procedure 273 286	NOD2 mutation
E7	Diagnostic_procedure:T14 
T15	Detailed_description 260 272	heterozygous
R4	MODIFY Arg1:T15 Arg2:E7	
T16	Diagnostic_procedure 288 295	p.R334W
E8	Diagnostic_procedure:T16 
R5	IDENTICAL Arg1:E8 Arg2:E7	
T17	Medication 362 377	corticosteroids
E9	Medication:T17 
T18	Administration 345 352	topical
T19	Administration 357 361	oral
R6	MODIFY Arg1:T19 Arg2:E9	
R7	MODIFY Arg1:T18 Arg2:E9	
T20	Duration 383 397	over the years
E10	Duration:T20 
T21	Disease_disorder 398 415	visual impairment
E11	Disease_disorder:T21 
T22	Detailed_description 416 426	progressed
R8	MODIFY Arg1:T22 Arg2:E11	
A1	TREND E11 INC
T23	Disease_disorder 298 316	Ocular involvement
E12	Disease_disorder:T23 
T24	Detailed_description 331 341	controlled
R9	MODIFY Arg1:E9 Arg2:T24	
R10	MODIFY Arg1:T24 Arg2:E12	
T25	Disease_disorder 452 465	Blau syndrome
E13	Disease_disorder:T25 
T26	Disease_disorder 467 476	arthritis
E14	Disease_disorder:T26 
T27	Sign_symptom 481 485	rash
E15	Sign_symptom:T27 
R11	MODIFY Arg1:E13 Arg2:E14	
R12	MODIFY Arg1:E13 Arg2:E15	
T28	Duration 496 505	over time
E16	Duration:T28 
T29	Detailed_description 487 495	subsided
R13	MODIFY Arg1:T29 Arg2:E15	
R14	MODIFY Arg1:T29 Arg2:E14	
A2	TREND E15 DEC
A3	TREND E14 DEC
T30	Disease_disorder 517 527	panuveitis
E17	Disease_disorder:T30 
T31	Detailed_description 507 516	Bilateral
R15	MODIFY Arg1:T31 Arg2:E17	
T33	Medication 589 601	methotrexate
E18	Medication:T33 
T34	Detailed_description 528 538	progressed
R16	MODIFY Arg1:T34 Arg2:E17	
T35	Disease_disorder 619 631	inflammation
E19	Disease_disorder:T35 
T36	Biological_structure 612 618	ocular
R17	MODIFY Arg1:T36 Arg2:E19	
T37	Detailed_description 632 641	persisted
R18	MODIFY Arg1:T37 Arg2:E19	
T38	Medication 672 679	steroid
E20	Medication:T38 
T39	Administration 680 690	injections
T40	Detailed_description 666 671	local
R19	MODIFY Arg1:T40 Arg2:T39	
R20	MODIFY Arg1:T39 Arg2:E20	
T41	Medication 727 755	methylprednisolone treatment
E21	Medication:T41 
T42	Administration 704 715	intravenous
T43	Administration 717 719	IV
R21	IDENTICAL Arg1:T43 Arg2:T42	
T44	Detailed_description 695 703	repeated
R23	MODIFY Arg1:T44 Arg2:T42	
*	OVERLAP E20 E21 E19 E18
T46	Medication 803 813	infliximab
E22	Medication:T46 
T50	Administration 858 860	IV
R26	MODIFY Arg1:T50 Arg2:E22	
T51	Date 939 978	1 year after this treatment was started
E23	Date:T51 
T52	Disease_disorder 979 986	uveitis
E24	Disease_disorder:T52 
T53	Severity 987 995	worsened
R28	MODIFY Arg1:T53 Arg2:E24	
T55	Medication 1017 1027	infliximab
E25	Medication:T55 
A4	TREND E25 DEC
T56	Detailed_description 1032 1044	discontinued
R29	MODIFY Arg1:T56 Arg2:E25	
T57	Medication 1046 1056	Adalimumab
E26	Medication:T57 
T58	Dosage 1058 1080	24 mg/m2 every 2 weeks
R30	MODIFY Arg1:T58 Arg2:E26	
T60	Medication 1119 1131	methotrexate
E27	Medication:T60 
T61	Dosage 1133 1148	15 mg/m2/weekly
R32	MODIFY Arg1:T61 Arg2:E27	
A5	TREND E27 INC
T49	Lab_value 1154 1163	increased
R27	MODIFY Arg1:T49 Arg2:E27	
T59	Disease_disorder 1174 1188	ocular disease
E28	Disease_disorder:T59 
T62	Detailed_description 1198 1204	active
R31	MODIFY Arg1:T62 Arg2:E28	
T63	Medication 1206 1227	Mycophenolate mofetil
E29	Medication:T63 
T64	Dosage 1229 1238	750 mg/m2
T65	Medication 1249 1258	abatacept
E30	Medication:T65 
T66	Dosage 1260 1274	10 mg/kg/month
T67	Administration 1275 1277	IV
R33	MODIFY Arg1:T66 Arg2:E30	
R34	MODIFY Arg1:T67 Arg2:E30	
R35	MODIFY Arg1:T64 Arg2:E29	
T70	Disease_disorder 1404 1411	lesions
E32	Disease_disorder:T70 
T71	Biological_structure 1396 1403	retinal
T72	Disease_disorder 1382 1395	granulomatous
E33	Disease_disorder:T72 
T73	Disease_disorder 1433 1445	inflammation
E34	Disease_disorder:T73 
T74	Biological_structure 1416 1432	anterior chamber
R36	MODIFY Arg1:T74 Arg2:E34	
T76	Medication 1551 1579	corticosteroid pulse therapy
E36	Medication:T76 
T77	Dosage 1640 1655	3 boluses/month
T78	Duration 1660 1680	6 consecutive months
E37	Duration:T78 
T79	Medication 1819 1830	canakinumab
E38	Medication:T79 
T80	Dosage 1802 1815	2 mg/kg/month
R37	MODIFY Arg1:T80 Arg2:E38	
T81	Lab_value 1626 1639	an average of
R38	MODIFY Arg1:T81 Arg2:T77	
R39	MODIFY Arg1:T77 Arg2:E36	
*	OVERLAP E36 E37 E35 E52
T75	Medication 1772 1800	IL-1 antibody administration
E35	Medication:T75 
R40	SUB_PROCEDURE Arg1:E38 Arg2:E35	
T82	Disease_disorder 1871 1883	ocular flare
E39	Disease_disorder:T82 
A7	POLARITY E39 NEG
T84	Medication 1900 1921	steroid pulse therapy
E41	Medication:T84 
A8	POLARITY E41 NEG
T83	Medication 1969 1981	methotrexate
E40	Medication:T83 
T85	Administration 1964 1968	oral
R41	MODIFY Arg1:T85 Arg2:E40	
T86	Medication 1995 2005	prednisone
E42	Medication:T86 
T87	Dosage 2007 2020	0.2 mg/kg/day
T88	Lab_value 1986 1994	low-dose
R42	MODIFY Arg1:T88 Arg2:E42	
R43	MODIFY Arg1:T87 Arg2:E42	
A9	TREND E40 STAY
A10	TREND E42 STAY
T89	Diagnostic_procedure 2057 2072	fluorangiograms
E43	Diagnostic_procedure:T89 
T91	Detailed_description 2137 2172	well tolerated with no side effects
T92	Diagnostic_procedure 2190 2206	laboratory tests
E44	Diagnostic_procedure:T92 
T93	Frequency 2218 2225	monthly
T94	Detailed_description 2232 2238	normal
R44	MODIFY Arg1:T94 Arg2:E44	
R45	MODIFY Arg1:T93 Arg2:E44	
T95	Medication 2124 2132	The drug
E45	Medication:T95 
#1	AnnotatorNotes E45	Likely a coreference, but unclear which drug it's referring to.
R46	MODIFY Arg1:T91 Arg2:E45	
*	OVERLAP E45 E44 E39 E41 E38 E40 E42 E43
R47	MODIFY Arg1:E2 Arg2:E1	
R48	MODIFY Arg1:E3 Arg2:E1	
R49	MODIFY Arg1:E4 Arg2:E1	
R50	MODIFY Arg1:E5 Arg2:E1	
*	OVERLAP E4 E5 E2 E3 E46
T90	Diagnostic_procedure 206 216	histologic
E46	Diagnostic_procedure:T90 
R51	MODIFY Arg1:E6 Arg2:E46	
R52	MODIFY Arg1:E46 Arg2:E1	
R53	MODIFY Arg1:E7 Arg2:E1	
*	OVERLAP E6 E7
*	OVERLAP E8 E12
R54	BEFORE Arg1:E9 Arg2:E10	
*	OVERLAP E10 E11 E15 E16 E14
T96	Date 789 801	age 10 years
E47	Date:T96 
T97	Date 545 556	age 5 years
E48	Date:T97 
R55	AFTER Arg1:E17 Arg2:E48	
R56	BEFORE Arg1:E48 Arg2:E18	
R57	BEFORE Arg1:E21 Arg2:E47	
*	OVERLAP E47 E22
R58	BEFORE Arg1:E22 Arg2:E23	
R59	BEFORE Arg1:E16 Arg2:E17	
*	OVERLAP E23 E24
T98	Date 1004 1010	age 12
E49	Date:T98 
R60	BEFORE Arg1:E24 Arg2:E49	
*	OVERLAP E49 E25
R61	BEFORE Arg1:E25 Arg2:E26	
*	OVERLAP E26 E27 E28
R62	BEFORE Arg1:E28 Arg2:E29	
R63	BEFORE Arg1:E29 Arg2:E30	
T68	Diagnostic_procedure 1311 1342	without significant improvement
E31	Diagnostic_procedure:T68 
A6	TREND E31 STAY
R64	BEFORE Arg1:E30 Arg2:E31	
T99	Date 1347 1359	age 16 years
E50	Date:T99 
R65	BEFORE Arg1:E31 Arg2:E50	
R66	MODIFY Arg1:T71 Arg2:E32	
R67	MODIFY Arg1:E33 Arg2:E32	
*	OVERLAP E50 E32 E34 E51
T100	Sign_symptom 1459 1464	edema
E51	Sign_symptom:T100 
T101	Biological_structure 1451 1458	macular
R68	MODIFY Arg1:T101 Arg2:E51	
T102	Disease_disorder 1489 1507	retinal detachment
E52	Disease_disorder:T102 
R69	BEFORE Arg1:E51 Arg2:E52	
T32	Dosage 828 879	5 mg/kg increased to 10 mg/kg IV every 4 to 6 weeks
R24	MODIFY Arg1:T32 Arg2:E22	
R22	MODIFY Arg1:T42 Arg2:E21	
T45	Duration 1844 1866	6 months that followed
E53	Duration:T45 
R25	MODIFY Arg1:E53 Arg2:E39	
